Crescent Biopharma, Inc. (CBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Crescent Biopharma, Inc. stock (CBIO) is currently trading at $10.44. Crescent Biopharma, Inc. PS ratio (Price-to-Sales) is 30.60. Analyst consensus price target for CBIO is $22.00. WallStSmart rates CBIO as Sell.
- CBIO PE ratio analysis and historical PE chart
- CBIO PS ratio (Price-to-Sales) history and trend
- CBIO intrinsic value — DCF, Graham Number, EPV models
- CBIO stock price prediction 2025 2026 2027 2028 2029 2030
- CBIO fair value vs current price
- CBIO insider transactions and insider buying
- Is CBIO undervalued or overvalued?
- Crescent Biopharma, Inc. financial analysis — revenue, earnings, cash flow
- CBIO Piotroski F-Score and Altman Z-Score
- CBIO analyst price target and Smart Rating
Crescent Biopharma, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Crescent Biopharma, Inc. (CBIO) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and price/sales. Significant fundamental concerns warrant caution or avoidance.
Crescent Biopharma, Inc. (CBIO) Key Strengths (1)
Trading at 1.67x book value, attractively priced
Crescent Biopharma, Inc. (CBIO) Areas to Watch (3)
Very expensive at 30.6x annual revenue
Very low institutional interest at 2.21%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Crescent Biopharma, Inc. (CBIO) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 8.0/10) while 3 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.67) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Institutional Own., Market Cap. Some valuation metrics including Price/Sales (30.60) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CBIO's Price-to-Sales ratio of 30.60x sits near its historical average of 32.29x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 13% below its historical high of 35.24x set in Mar 2026, and 0% above its historical low of 30.6x in Mar 2026.
Insider Transactions
Loading insider activity...
About Crescent Biopharma, Inc.(CBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.